Risk Factors for Retinal Hemorrhage after Photodynamic Therapy in Age-Related Macular Degeneration

The Global RDH12 Alliance unites inherited retinal disease advocacy groups including UK-based Eyes on the Future and the US-based RDH12 Fund for Sight

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The companies will focus their joint effort on extended-release therapies for ocular disease

Optical coherence tomography may help identify patients at risk of cardiovascular disease before coronary angiography